Abstract: The present disclosure discloses an optical imaging lens assembly including, sequentially from an object side to an image side along an optical axis, a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens, and an eighth lens having refractive power. At least one of the first lens to the eighth lens has an aspheric surface. A distance TTL along the optical axis from an object-side surface of the first lens to an imaging plane of the optical imaging lens assembly, a total effective focal length f of the optical imaging lens assembly and half of a diagonal length ImgH of an effective pixel area on the imaging plane of the optical imaging lens assembly satisfy the following conditional expressions: TTL/f?1.0, ImgH?6.0 mm and 1.0<TTL/ImgH<1.5.

Abstract: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.

Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.

Abstract: A camera lens group including, a first lens having positive refractive power, a convex object-side surface and a concave image-side surface; a second lens having refractive power, a convex object-side surface and a concave image-side surface; a third lens having negative refractive power and a concave image-side surface; a fourth lens having positive refractive power, a convex object-side surface and a concave image-side surface; a fifth lens having refractive power, a convex object-side surface and a concave image-side surface; a sixth lens having positive refractive power, a concave object-side surface and a convex image-side surface; a seventh lens having refractive power; an eighth lens having refractive power and a convex image-side surface; a ninth lens having refractive power, a concave object-side surface and a convex image-side surface; and a tenth lens having negative refractive power, a concave object-side surface and a concave image-side surface.

Abstract: Disclosed are a non-orthogonal multiple access (NOMA) multi-layer transmission method and an apparatus therefor. The method includes: a terminal determines a spread spectrum sequence group for NOMA multi-layer transmission, with the terminal being configured for NOMA multi-layer transmission, and the spread spectrum sequence group includes N spread spectrum sequences, the N spread spectrum sequences correspond to N data layers, the N spread spectrum sequences are mutually orthogonal, N is the number of data layers of NOMA multi-layer transmission, and N is an integer greater than 1; and the terminal sends data, the data comprising the N data layers using the spread spectrum sequence group for spectrum spreading.

Abstract: Embodiments of the present disclosure provide a method for identifying those entities within a network that have the most influence on other entities within the network. A multi-relational network comprising links among a plurality of physicians is generated based on peer network data, wherein each link indicates a first physician that influences a second physician, and a weight of the influence. A decision by a treating physician of the plurality of physicians is decomposed, using a deep learning engine, into a magnitude of peer influence and a magnitude of control factor influence based on the multi-relational network and a plurality of control factors respectively. The magnitude of peer influence among one or more physicians in the multi-relational network is distributed among physicians in the multi-relational network based on the links each physician maintains with other physicians.

Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: Disclosed are a transmission delay indication method and device. In the embodiments of the present disclosure, a network device determines a common transmission delay of at least one cell, and sends the common transmission delay to a terminal in the at least one cell. The common transmission delay is used for the terminal in the at least one cell to determine a transmission timing sequence with a network side.

Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

Abstract: The present invention relates to a salt of (6-(4-((4-(1H-pyrazol-4-yl)phenypamino)pyrimidin-2 -yl)-1-methyl-1H-indo1-2-yl)(3,3-difluoroazetidine-1-yl)methanone (hereinafter referred to as “compound A”), a solid form of the salt, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

Abstract: A preparation method for a novel Rho-related protein kinase inhibitor having the structure of formula A and an intermediate in the preparation method.

Abstract: A method for preventing, alleviating and/or treating graft versus host disease caused by hematopoietic stem cell transplantation, which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof to an individual in need thereof.

Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.

Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.

Abstract: Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a preparation and use of the above inhibitor.

Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.

Abstract: The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).

Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.

Abstract: The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.